
Commentary|Videos|May 24, 2013
The Treatment of Bladder Cancer
Author(s)Robert Dreicer, MD, MS, MACP, FASCO
Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, discusses the treatment of bladder cancer.
Advertisement
Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, discusses the treatment of bladder cancer.
Clinical Pearls
Bladder cancer has been difficult to treat for two reasons: It is an aggressive epithelial cancer and has been treated primarily with chemotherapy. MLN8237 and other compounds are being looked at in phase II studies to generate enthusiasm for phase III trials.
- Bladder cancer is an aggressive epithelial cancer and has been primarily treated with chemotherapy
- MLN8237 and other compounds are in phase II studies, looking to generate enthusiasm for large phase III trials
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5







































